The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
10.1002/cncr.31701 · doi-reference
Neoadjuvant selpercatinib for advanced medullary thyroid cancer
10.1002/hed.26527 · doi-reference
Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series
10.1089/thy.2022.0506 · doi-reference
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
10.1200/jco.22.01351 · doi-reference
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?
10.1080/14737140.2022.2069097 · doi-reference
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
10.1089/thy.2019.0133 · doi-reference
A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1)
10.1182/blood-2021-148103 · doi-reference
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
10.1038/s41698-023-00449-x · doi-reference
First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation
10.1200/jco.2022.40.16_suppl.3003 · doi-reference
Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers
10.1200/jco.2022.40.16_suppl.105 · doi-reference
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
10.1200/jco.2023.41.17_suppl.lba3000 · doi-reference
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
10.1016/s1470-2045(23)00275-9 · doi-reference
Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation
10.1200/jco.23.00434 · doi-reference
Dostarlimab: A Review
10.3390/biom12081031 · doi-reference
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.001 · doi-reference
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
10.1200/jco.21.01440 · doi-reference
Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer
10.1038/s41598-021-91974-x · doi-reference
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >/=10: a decision centered on empowering patients and their physicians
10.1016/j.annonc.2020.07.002 · doi-reference
Tumor mutation burden: from comprehensive mutational screening to the clinic
10.1186/s12935-019-0929-4 · doi-reference
A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
10.1038/s41598-022-23319-1 · doi-reference
Microsatellite instability: a review of what the oncologist should know
10.1186/s12935-019-1091-8 · doi-reference
Tumor Mutation Burden and Cancer Treatment
10.1001/jamaoncol.2020.6371 · doi-reference
Pembrolizumab (Keytruda)
10.1080/21645515.2016.1199310 · doi-reference
Larotrectinib: First Global Approval
10.1007/s40265-018-1044-x · doi-reference
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
10.1016/s1470-2045(19)30856-3 · doi-reference
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
10.1016/s1470-2045(19)30691-6 · doi-reference
NTRK fusions in solid tumours: what every pathologist needs to know
10.1016/j.pathol.2023.05.002 · doi-reference
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
10.1136/esmoopen-2015-000023 · doi-reference
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
10.1038/ng0298-184 · doi-reference
NTRK fusion-positive cancers and TRK inhibitor therapy
10.1038/s41571-018-0113-0 · doi-reference
Targeting TRK family proteins in cancer
10.1016/j.pharmthera.2017.02.006 · doi-reference
Strategies for Mitigating Adverse Events Related to Selective RET Inhibitors in Patients with RET-altered Cancers
10.1016/j.xcrm.2023.101332 · doi-reference
Efficacy of selpercatinib in RET-altered thyroid cancers
10.1056/nejmoa2005651 · doi-reference
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
10.1056/nejmoa2005653 · doi-reference
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
10.1016/s1470-2045(22)00541-1 · doi-reference
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
10.1177/17588359231177015 · doi-reference
